Latest Mixed state Stories
A Rhode Island Hospital psychiatrist and researcher explains the negative impact of broadening the diagnostic criteria for bipolar disorder in the upcoming Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).
Recognition of bipolar disorder in adolescents is now clearly established. However, whether bipolarity exists in children remains controversial despite numerous studies that have been conducted on this topic in the last fifteen years.
The evidence base for the prescribing of aripiprazole in maintenance treatment of bipolar disorder is limited to a single trial, sponsored by the manufacturer of aripiprazole.
SILVER SPRING, Md., Jan. 21, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Viibryd tablets (vilazodone hydrochloride) to treat major depressive disorder in adults.
WILMINGTON, Del., April 30 /PRNewswire/ -- Following last year's efforts to support bipolar depression awareness and education, AstraZeneca (NYSE: AZN) is relaunching The Bipolar Journey: Living With Bipolar Depression interactive exhibit in a second tour to patients and caregivers across America.
WALTHAM, Mass., April 30 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the United States Patent and Trademark Office has granted a Notice of Allowance of a patent covering the use of uridine in the treatment of patients with bipolar disorder.
INDIANAPOLIS, Dec. 4 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) today approved ZyprexaÂ® (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years old.
WILMINGTON, Del., Dec.
PHILADELPHIA, Sept. 2 /PRNewswire/ -- Pfizer, Inc.